Curaleaf’s latest proposal includes a mix of 0.4013 subordinate voting shares and US$1.00 in cash for each Aurora share. While the bidder is pushing forward, Aurora leadership insists that the move is merely a procedural step rather than an immediate catalyst for investor decisions. CEO Miguel Martin emphasized that shareholders should allow the company time to evaluate the terms fully before committing to any course of action.
Investors have until at least December 4, 2026, to weigh their options. The board intends to issue a formal recommendation and a director’s circular once the internal review concludes. In the interim, Aurora has engaged Kingsdale Advisors to assist shareholders with inquiries regarding the bid, directing them to the company’s dedicated resource portal for updates.
Comments (0)
No comments yet. Be the first!